PharmaCorp is testing for sexual side effects in its new antidepressant Hapinis. They have some sort of sexual health score which is measured for a pa

PharmaCorp is testing for sexual side effects in its new antidepressant Hapinis. They have some sort of sexual health score which is measured for a patient before taking Hapinis and after a year of taking Hapinis. This score has a maximum of 100 (ideal sexual health), and a minimum of 0 (worst possible sexual health). They consider an average decrease in sexual health of 0.2 or more to be unacceptable. If it can be shown that sexual health decreases, on average, by this much or more, then PharmaCorp will pull Hapinis from the market. They have tested 9 patients, producing the results below. Patient After Before Difference (Before Minus After) 0001 63 64 1 0002 81 76 -5 0003 42 46 4 0004 100 98 -2 0005 25 24 -1 0006 43 46 3 0007 40 47 7 0008 39 36 -3 0009 87 85 -2 Mean 57.778 58.000 0.222 Sample Standard Deviation 26.013 24.336 3.833 PharmaCorp plans to build a 95% confidence interval and perform a significance test (at 5% significance) to see if Hapinis needs to be pulled from the market. For convenience, we will define the following. let µB = the mean sexual health score of patients before taking Hapinis let µA = the mean sexual health score of patients after 1 year of taking Hapinis PharmaCorp will be performing inference about µB – µA, i.e. the mean decrease in sexual health. What is PharmaCorp’s confidence interval? A. (-27.159, 27.604) B. (-2.724, 3.169) C. (-0.657, 1.101) D. (0.156, 0.288)

Posted in Uncategorized